Press Releases on November 12, 2024 - EIN Presswire - Press Release Distribution Service

Published on November 12, 2024 - 21:05 GMT

Lifecore Biomedical to Present at Stephens Annual Investment Conference

CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the company’s president and chief …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2024 - 21:05 GMT

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

Westrock Coffee Company to Participate in the Stephens Annual Investment Conference

LITTLE ROCK, Ark., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Westrock Coffee Company (NASDAQ: WEST) (“Westrock Coffee” or the “Company”) today announced that the Company will be participating in the Stephens Annual Investment Conference, which will be held …

Distribution channels: Culture, Society & Lifestyle ...

Published on November 12, 2024 - 21:05 GMT

Titan Machinery Inc. to Report Fiscal Third Quarter Ended October 31, 2024 Results on Tuesday, November 26, 2024

WEST FARGO, N.D., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, announced today it will release financial results for the third quarter ended October …

Distribution channels: Technology ...

Published on November 12, 2024 - 21:05 GMT

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners …

Distribution channels: Business & Economy, Technology ...

Published on November 12, 2024 - 21:05 GMT

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of Mydcombi in its second generation Optejet device Announced …

Distribution channels: Business & Economy, Technology ...

Published on November 12, 2024 - 21:05 GMT

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

MARA Announces Third Quarter 2024 Results

Fort Lauderdale, FL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a letter to shareholders, MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, …

Distribution channels: Banking, Finance & Investment Industry ...

Published on November 12, 2024 - 21:05 GMT

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on November 12, 2024 - 21:05 GMT

QIAGEN und McGill University starten Partnerschaft zur Förderung der Mikrobiomforschung

QIAGEN und die McGill University initiieren gemeinsame Projekte im Bereich der Mikrobiomforschung, um evidenzbasiertes Wissen für die Medizin und die öffentliche Gesundheit zu generieren //McGill dient als Beta-Teststelle für neue Mikrobiom-Lösungen von …

Distribution channels: Companies, Technology ...

Published on November 12, 2024 - 21:05 GMT

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended …

Distribution channels: ...

Published on November 12, 2024 - 21:05 GMT

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2024 - 21:05 GMT

Oportun Completes Sale of its Credit Card Portfolio

SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven financial services company, today announced that it has closed the previously agreed upon sale of its credit card portfolio to Continental Finance. Completing …

Distribution channels: Banking, Finance & Investment Industry, Media, Advertising & PR ...

Published on November 12, 2024 - 21:05 GMT

HF Foods Reports Third Quarter 2024 Financial Results

Increase in Net Revenue as Company Continues to Execute Operational Transformation Plan Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” …

Distribution channels:

Published on November 12, 2024 - 21:05 GMT

FibroGen Reports Third Quarter 2024 Financial Results

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) …

Distribution channels: Business & Economy, Technology ...

Published on November 12, 2024 - 21:05 GMT

Interparfums, Inc. Announces Initial 2025 Guidance

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2025. Guidance 2024E % Change 2025E Net Sales $1.45B +4% $1.51B …

Distribution channels: Consumer Goods, Media, Advertising & PR ...

Published on November 12, 2024 - 21:05 GMT

SoundThinking Reports Third Quarter 2024 Financial Results

Revenues Increased 10% to $26.3 Million, Driven by New and Existing Customer Growth Company Reaffirms FY 2024 Revenue Guidance Range of $104.0 Million to $106.0 Million, Representing 13% Year-Over-Year Growth at the Midpoint, and FY 2024 Adjusted EBITDA …

Distribution channels: